Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Resolution of subjective symptoms was achieved in 63% of cases; AST diminished on average by 36%, ALT by 34% and GGT by 46%. Furthermore, the investigators reported a reduction in hepatomegaly ...

Patients on both part 1a and part 1b of the study experienced grade 3 or higher diarrhea (5%), hypertension (17%), neutropenia (7%), ALT/AST increase (5%), anemia ... %), fatigue (55%), high blood ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

H.C. Wainwright analyst Robert Burns increased the price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $45.00 from $42.00, while reiterating a Buy rating on the company's shares. Currently ...

Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION ...

Correspondence to Dr Preeti Malik, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; pmalik.ma{at}gmail.com Objective To evaluate association between biomarkers and outcomes in ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

AST SpaceMobile (ASTS) announced an agreement for long-term access to up to 45 MHz of lower mid-band spectrum in the United States for direct-to-device satellite applications. This agreement ...